Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes

Journal of Medicinal Chemistry

Volumn 46, Issue 13, 2003, Pages 2683-2696

  Michellys, P Y ^a   Ardecky, R J ^a   Chen, J H ^a   Crombie, D L ^a,b   Etgen, G J ^a,d   Faul, M M ^a,d   Faulkner, A L ^a,c   Grese, T A ^a,d   Heyman, R A ^a,e   Karanewsky, D S ^a,g   Klausing, K ^a   Leibowitz, M D ^a   Liu, S ^a   Mais, D A ^a   Mapes, C M ^a   Marschke, K B ^a   Reifel Miller, A ^a,d   Ogilvie, K M ^a,f   Rungta, D ^a   Thompson, A W ^a,h   Tyhonas, J S ^a   Boehm, M F ^a,b   more..

^a LIGAND PHARMACEUTICALS INC   (United States)

^b BIOGEN   (United States)

^c PROCTER AND GAMBLE COMPANY   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e EXELIXIS INC   (United States)

^f PFIZER INC   (United States)

^g GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^h ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLOCTA 2,4,6 TRIENOIC ACID; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; BEXAROTENE; RETINOID X RECEPTOR; THYROID HORMONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MICE; OCTANOIC ACIDS; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS;

EID: 0038454672     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020340q     Document Type: Article

References (45)

1. Orfanos, C. E.; Ehlert, R.; Gollnick, H. The Retinoids. A Review of Their Clinical Pharmacology and Therapeutic Use. [Review] Drugs 1987, 34, 459-503.
2. Peck, G. L.; DiGiovanna, J. J.; Synthetic Retinoids in Dermatology. In The Retinoids: Biology, Chemistry, and Medicine, 2nd ed.; Raven Press: New York, 1994; pp 631-658.
3. Orfanos, C. E.; Zoubouli, C. C.; Almond-Roesler, B.; Geilen, C. C. Current Use and Future Potential Role of Retinoids in Dermatology. [Review] J. Clin. Oncol. 1997, 53, 358-388.
4. Boehm, M. F.; Heyman, R. A.; Patel, S.; Stein, R. B.; Nagpal, S. Retinoids: Biological Function and Use in the Treatment of Dermatological Diseases. Expert Opin. Invest. Drugs 1995, 4, 593-612.
5. Rosen, J.; Day, A.; Jones, T. K.; Turner Jones, T.; Nadzan, A. M.; Stein, R. B. Intracellular Receptors and Signal Transducers and Activators of Transcription Superfamilies: Novel Targets for Small-Molecule Drug Discovery. J. Med. Chem. 1995, 38, 4855-4874.
6. Mangelsdorf, D. J.; Unesono, K.; Evans, R. M.; The Retinoid Receptor. In The Retinoids: Biology, Chemistry, and Medicine, 2nd ed.; Raven Press: New York, 1994; pp 319-349.
7. Heyman, R. A.; Mangelsdorf, D. J.; Dyck, J. A.; Stein, R. B.; Eichele, G.; Evans, R. M.; Thaller, C. 9-Cis Retinoic Acid Is a High Affinity Ligand for the Retinoid Receptor. Cell 1992, 68, 397-406.
8. Levin, A. A.; Sturzenbecker, L. J.; Kazmer, S.; Bosakowski, T.; Huselton, C.; Allenby, G.; Speck, J.; Kratzeisen, C.; Rosenberg, M.; Lovey, A.; Grippo, J. F. 9-Cis Retinoic Acid Stereoisomer Binds and Activates the Nuclear Receptor RXRα. Nature 1992, 355, 359-361.
9. Boehm, M. F.; Zhang, L.; Badea, B. A.; White, S. K.; Mais, D. E.; Berger, E.; Suto, C. M.; Goldman, M. E.; Heyman, R. A. Synthesis and Structure - Activity Relationships of Novel Retinoid X Receptor-Selective Retinoids. J. Med. Chem. 1994, 37, 2930-2941.
10. Sola, X. C.; Kupper, T. A New Rexinoid for Cutaneous T-Cell Lymphoma. Arch. Dermatol. 2001, 137, 649-652.
11. Duvic, M.; Hymes, K.; Heald, P.; Breneman, D.; Martin, A. G.; Mykowski, P.; Crowley, C.; Yocum, R. C. Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-cells Lyraphoma: Multinational Phase II-III Trial Results. J. Clin. Oncol. 2001, 19, 2456-2471.
12. Wong, S.-F. Oral Bexarotene in the Treatment of Cutaneous T-cell Lymphoma. Ann. Pharmacother. 2001, 35, 1056-1065.
13. Khuri, F. R.; Rigas, J. R.; Figlin, R. A.; Gralla, R. J.; Shin, D. M.; Munden, R.; Fox, N.; Huyghe, M. R.; Kean, Y.; Reich, S. D.; Hong, W. K. Multi-Institutional Phase I/II Trial of Oral Bexarotene in Combination with Cisplatin and Vinorelbine in Previously Untreated Patients with Advanced Nonsmall-Cell Lung Cancer. J. Clin. Oncol. 2001, 19, 2626-2637.
14. Boehm, M. F.; Zhang, L.; Zhi, L.; McClurg, R.; Berger, E.; Wagoner, M.; Mais, D. E.; Suto, C. M.; Davies, P. J. A.; Heyman, R. A.; Nazdan A. M. Design and Synthesis of Potent Retinoid X Receptor Selective Ligands That Induce Apoptosis in Leukemia Cells. J. Med. Chem. 1995, 38, 3146-3155.
15. Canan Koch, S. S.; Dardashti, L. J.; Cesario, R. M.; Coston, G. E.; Boehm, M. F.; Heyman R. A.; Nazdan A. M. Synthesis of Retinoid X Receptor-Specific Ligands That Are Potent Inducers of Adipogenesis in 3T3-L1 Cells. J. Med. Chem. 1999, 42, 742-750.
16. Faul, M. M.; Ratz, A. M.; Sullivan, K. A.; Trankle, W. G.; Winneroski, L. L. Synthesis of Novel Retinoid X Receptor-Selective Retinoids. J. Org. Chem. 2001, 66, 5772-5782.
17. Schulman, I. G.; Crombie, D.; Bissonnette, R. P.; Cesario, R.; Roegner, K.; Shao, G.; Heyman, R. A. RXR-Specific Agonists and Modulators: A New Retinoid Pharmacology. In Handbook of Experimental Pharmacology; Springer-Verlag: Berlin, 1999; Vol. 139, pp 215-235 and references therein.
18. Nagpal, S.; Chandraratna, R. A. S. Recent Development in Receptor-Selective Retinoids. Curr. Pharm. Des. 2000, 6, 919-931 and references therein.
19. Willson, T. M.; Brown, P. J.; Sternbach, D. D.; Henke, B. R. The PPARs: From Orphan Receptors to Drug Discovery. J. Med. Chem. 2000, 44, 527-550 and references therein.
20. Lehnard, J. M. PPARγ/RXR as a Molecular Target for Metabolic Diseases. Recept. Channels 2001, 7, 249-258.
21. Jones, A. B. Peroxisome Proliferator-Activated Receptor (PPAR) Modulators: Diabetes and Beyond. Med. Res. Rev. 2001, 21, 540-552.
22. Isserman, I.; Green, S. Activation of a Member of the Steroid Hormone Receptor Superfamily by Peroxisome Proliferators. Nature 1990, 347, 645-650.
23. Stumvoll, M.; Haring, H. Insulin Resistance and Insulin Sensitizers. Horm. Res. 2001, 55 (Suppl. 2), 3-13.
24. Mukherkjee, R.; Davies, P. J. A.; Crombie, D. L.; Bischoff, E. D.; Cesario, R. M.; Jow, L.; Hamann, L. G.; Boehm, M. F.; Mondon, C. E.; Nazdan, A. M.; Paterniti, J. R.; Heyman, R. A. Sensitization of Obese Mice to Insulin by Retinoid X Receptor Agonists. Nature 1997, 386, 407-410.
25. Vuligonda, V.; Thacher, S. M.; Chandraratna, R. A. S. Enantio-selective Syntheses of Potent Retinoid X Receptor Ligands: Differential Biological Activities of Individual Antipodes. J. Med. Chem. 2001, 44, 2298-2303.
26. Cesario, R. M.; Klausing, K.; Razzaghi, H.; Crombie, D. L.; Rungta, D.; Heyman, R. A.; Lala, D. The Retinoid LG100754 Is a Novel RXR/PPARγ Agonist and Decreases Glucose Levels In Vivo. Mol. Endocrinol. 2001, 15, 1360-1369.
27. Yamauchi, T.; Waki, H.; Kamon, J.; Murakami, K.; Motojima, K.; Komeda, K.; Miki, H.; Kubota, N.; Terauchi, Y.; Tsuchida, A.; Tsuboyama-Kasaoda, N.; Yamauchi, N.; Ide, T.; Hori, W.; Kato, S.; Fukayama, M.; Akanuma, Y.; Ezaki, O.; Itai, A.; Nagai, R.; Kimura, S.; Tobe, K.; Kagechika, H.; Shudo, K.; Kadowaki, T. Inhibition of RXR and PPARγ Ameliorates Diet-Induced Obesity and Type 2 Diabetes. J. Clin. Invest. 2001, 108, 1001-1013.
28. Zhang, L.; Nazdan, A. M.; Heyman, R. A.; Love, D. L.; Mais, D. E.; Croston, G. E.; Lamph, W. W.; Boehm, M. F. Discovery of Novel Retinoic Acid Receptor Agonists Having Potent Antiproliferative Activity in Cervical Cells. J. Med. Chem. 1996, 39, 2659-2663.
29. Jorgenson, M.; Preparation of Ketones from the Reaction of Organolithium Reagents with Carboxylic Acids. Org. React. 1970 18, 1-97.
30. Hamann, L. G.; An Efficient Stereospecific Synthesis of the Dimer-Selective Retinoid X Receptor Modulator (2E,4E,6Z)-7- [5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-(n-propoxy)naphthalen- 3-yl]-3-methylocta-2,4,6-trienoic Acid. J. Org. Chem. 2000, 65, 3233-3235.
31. Nishinaga, A.; Iwasaki, H.; Shimizu, T.; Toyoda, Y.; Matsuura, T. Oxygenation of tert-Butylphenols with an Unsaturated Side Chain. J. Org. Chem. 1986, 51, 2257-2266.
32. Kallianos, A. G.; Warfield, A. H.; Melvyn, I. S. 3,5-Disubstituted-2-hydroxy Acetophenones. U.S. Patent 3,787,501, 1974.
33. Wada, A.; Nomoto, Y.; Tano, K.; Yamashita, E.; Ito, M. Synthesis of 9Z-9-Substituted Retinoic Acids by Palladium Catalyzed Coupling Reaction of a Vinyl Triflate with Alkenyl Stannanes. Chem. Pharm. Bull. 2000, 49, 1391-1394.
34. Pazos, Y.; De Lera, A. Stereoselective Synthesis of 9-cis-Retinoic Acid by Suzuki Reaction. Tetrahedron. Lett. 1999, 40, 8287-8290.
35. Wada, A.; Hiraishi, S.; Ito, M. Stereoselective Synthesis of 7E,9E-and 7E,9E-β-Ionyldeneacetaldehydes by Use of Tricarbonyl Iron Complex. Chem. Pharm. Bull. 1994, 42, 757-760.
36. Jansen, F. J. H. M.; Lugtenburg, J. Synthesis and Characterization of all-E-(4,4′-13C2)-Astaxanthin. Strategies for Labelling the C15-End Groups of Carotenoids. Eur. J. Org. Chem. 2000, 5, 829-836.
37. Dominguez, B.; Pazos, Y.; De Lera, A. R. Stereocontrolled Synthesis of 6-s-cis- and 6-s-trans-Locked 9Z-Retinoids by Hydroxyl-Accelerated Stille Coupling of(Z)-tri-n-Butylstannylbut-2-en-1-ol and Bicyclic Dienyl Triflates. J. Org. Chem. 2000, 65, 5917-5925.
38. For a review of dianion chemistry, see: Thompson, C. M. Dianion Chemistry in Organic Synthesis; CRC Press: Boca Raton, FL, 1994.
39. Liu, S.; Ogilvie, K. M.; Klausing, K.; Lawson, M. A.; Jolley, D.; Danmei, L.; Bilakovics, J.; Pascual, B.; Hein, N.; Urcan, M.; Leibowitz, M. D. Mechanism of Selective Retinoid X Receptor Agonist-Induced Hypothyroidism in the Rat. Endocrinology, in press.
40. Schultz, Tu, H., Jr.; Luk, A.; Repa, J. J.; Medina, J. C.; Li, L.; Schwendner, S.; Wang, S.; Thoolen, M.; Mangelsdorf, D. J.; Lustig, K. D.; Shan, B. Role of LXRs in Control of Lipogenesis. Genes Dev. 2000, 14, 2831-2838.
41. Cannan Koch, S. S.; Dardashti, L. J.; Hebert, J. J.; White, S. K.; Croston, G. E.; Flatten, K. S.; Heyman, R. A.; Nazdan, A. M. Identification of the First Retinoic X Receptor Homodimer Antagonist. J. Med. Chem. 1996, 39, 3229-3234.
42. Lala, D. S.; Mukherjee, R.; Schulman, I. G.; Cannan Koch, S. S.; Dardashti, L. J.; Nazdan, A. M.; Croston, G. E.; Evans, R. M.; Heyman, R. A. Activation of Specific Heterodimers by an Antagonist of RXR Homodimers. Nature 1996, 383, 450-453.
43. This unusual effect is know as the phantom ligand effect. See: Schulman, I. G.; Chuan, L.; Scwabe, J. W. R.; Evans, R. M. The Phantom Ligand Effect: Allosteric Control of Transcription by the Retinoid X Receptor. Genes & Dev. 1997, 11, 299-308.
44. Standeven, A. M.; Thacher, S. M.; Yuan, Y.-D.; Escobar, M.; Vuligonda, V.; Beard, R. L.; Chadraratna, A. S. Retinoid X Receptor Agonist Elevation of Serum Triglycerides in Rats by Potentiation of Retinoic Acid Receptor Agonist Induction or by Action as Single Agents. Biochem. Pharmacol. 2001, 62, 1501-1509.
45. Weatherman, R. V.; Fletterick, R. J.; Scanlan, T. S. Nuclear-Receptor Ligands and Ligand-Binding Domains. Annu. Rev. Biochem. 1999, 68, 559-581.